Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Shi Dong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-6679-725X; OpenAlex author ID A5112437014. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2021: 1 paper · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers

Papers 11

  1. Long non-coding RNA MIR4435-2HG promotes pancreatic cancer progression by regulating ABHD17C through sponging miR-128-3p. Co-author DOI 10.21037/tcr-24-51↗
  2. Ciprofol suppresses proliferation, invasion and migration of human pancreatic cancer cells. First author DOI 10.36721/pjps.2024.37.2.reg.327-336.1↗
  3. Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer. Co-author DOI 10.32604/or.2023.026959↗
  4. Integrated transcriptomics, proteomics and metabolomics-based analysis uncover TAM2-associated glycolysis and pyruvate metabolic remodeling in pancreatic cance… Co-author DOI 10.3389/fimmu.2023.1170223↗
  5. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Reveals That TAM2-Driven Genes Affect Immunotherapeutic Response and Prognosis in Pancreatic … First author DOI 10.3390/ijms241612787↗
  6. Nomograms for Predicting the Risk and Prognosis of Liver Metastases in Pancreatic Cancer: A Population-Based Analysis. Co-author DOI 10.3390/jpm13030409↗
  7. Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression. Co-author DOI 10.3389/fimmu.2022.1038650↗
  8. Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations. Co-author DOI 10.3389/fimmu.2022.844401↗
  9. Challenges and Opportunities Associated With Platelets in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.850485↗
  10. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Co-author DOI 10.3390/biom12101450↗
  11. Current understanding of ferroptosis in the progression and treatment of pancreatic cancer. Co-author DOI 10.1186/s12935-021-02166-6↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wence Zhou · 9 shared papers, 2021–2024 · strength 1.77
  2. Zhou Chen · 5 shared papers, 2021–2024 · strength 1.02
  3. Xin Li · 5 shared papers, 2021–2023 · strength 0.90
  4. Huaqing Shi · 4 shared papers, 2022–2024 · strength 0.86
  5. Wenkai Jiang · 4 shared papers, 2022–2023 · strength 0.78
  6. Ru He · 3 shared papers, 2022–2023 · strength 0.55
  7. Yan Du · 2 shared papers, 2023–2024 · strength 0.45
  8. Fangfang Han · 2 shared papers, 2022–2024 · strength 0.43
  9. Wence Zhou · 2 shared papers, 2023–2024 · strength 0.43
  10. Ru He · 1 shared paper, 2024 · strength 0.26
  11. Chunlu Dong · 1 shared paper, 2024 · strength 0.24
  12. Wancheng Li · 1 shared paper, 2023 · strength 0.20
  13. Hui Zhang · 1 shared paper, 2023 · strength 0.20
  14. Xin Li · 1 shared paper, 2023 · strength 0.20
  15. Hao Ming Xu · 1 shared paper, 2022 · strength 0.20
  16. Weixiong Zhu · 1 shared paper, 2022 · strength 0.19
  17. Hui Zhang · 1 shared paper, 2023 · strength 0.18
  18. Hui Tang · 1 shared paper, 2023 · strength 0.18
  19. Wenkai Jiang · 1 shared paper, 2021 · strength 0.17
  20. Zhengfeng Wang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.